China Microbial CRDMO Stability Study Services: A 2026 Guide

Biopharmaceutical developers seeking stability study services within a microbial CRDMO framework in China face a specific set of technical and regulatory demands. Microbial-derived biologics—recombinant proteins, nanobodies, plasmid DNA, and nucleic acid therapeutics—require rigorous stability characterization to support IND filings, clinical supply, and eventual commercial approval. Yaohai Bio-Pharma, operating as Yaohai Bio-Pharmaceutical under the Yaohai Bio-Pharma brand, positions itself as a microbial CRDMO (Contract Research, Development, and Manufacturing Organization) that integrates stability study work directly into its broader analytical, formulation, and manufacturing service chain.

Why Stability Studies Matter in Microbial Biologics Development

Stability testing is not an isolated checkbox in biologic drug development—it is a continuous thread running from early analytical characterization through formulation development, GMP manufacturing, and regulatory submission. For microbial expression systems, where proprietary refolding technology and high-yield fermentation processes are used to address aggregation in scFv/Fab fragments, stability data serves as objective evidence that a molecule’s structure, purity, and potency remain consistent over time and across storage conditions.

Within Yaohai Bio-Pharma’s capability system, stability studies are explicitly embedded in two interconnected service areas: Analytical Development & Quality Control and Formulation Development & Drug Product Manufacturing. In the analytical domain, stability studies are paired with specification development and batch release testing, supported by more than 50 analytical methods covering protein identity, purity, concentration, potency, and impurity analysis, as well as physicochemical and microbiological testing. In the formulation domain, stability studies accompany lyophilization process development, injectable formulation work, and drug product process transfer—meaning stability data generation is not a standalone deliverable but a continuous checkpoint across the product lifecycle.

A China-Based Microbial CRDMO with Global Reach

Founded in 2010, Yaohai Bio-Pharma has built its strategic positioning specifically around microbial expression systems rather than generic mammalian platforms. This specialization responds directly to industry pain points: low yields and stability issues common in mammalian expression systems, severe aggregation in scFv/Fab antibody fragments, high biopharmaceutical manufacturing costs, and the complex regulatory hurdles associated with entering the US, China, and EU markets simultaneously.

The company’s business coverage spans the global market, including the USA, China, Europe, and Australia—a footprint that matters for any sponsor whose stability study requirements must eventually align with multiple regulatory jurisdictions. Operating from China, Yaohai Bio-Pharma reports a track record in US-China dual submissions and Australian filings, along with European and Australian clinical trial registrations, suggesting that stability data packages generated through its analytical and formulation teams are structured with cross-border submission requirements in mind.

Technical Infrastructure Supporting Stability Workflows

Stability study services do not exist independently of manufacturing infrastructure. Yaohai Bio-Pharma operates 7,500L of total drug substance capacity across five production lines—ranging from 50L small scale to 2,000L large scale—along with two drug product fill-finish lines. This scale allows stability samples to be generated from representative, process-relevant batches rather than isolated bench-scale preparations, which strengthens the relevance of resulting stability data for regulatory purposes.

The company’s technology platforms—an E. coli expression platform, a yeast expression platform, and the RNASUP mRNA platform with LNP encapsulation technologies including SORT LNP and AbLNP—each present distinct stability considerations. Protein-based biologics require monitoring of aggregation, degradation, and potency over time; nucleic acid therapeutics such as mRNA and circRNA introduce additional storage and encapsulation-related stability variables. Yaohai Bio-Pharma’s capability description notes mRNA synthesis, modification, purification, and analytical characterization alongside LNP formulation and delivery development, indicating that stability assessment methodologies are adapted to the specific modality under study rather than applied as a one-size-fits-all protocol.

Quality Assurance and Facility Credentials

Any stability study program is only as credible as the facility and quality system generating the underlying data. Yaohai Bio-Pharma operates triple ISO-certified and EU QP-audited facilities. These third-party certifications provide an external reference point for sponsors evaluating whether a CRDMO’s stability testing environment meets the controlled conditions, documentation standards, and quality oversight expected by global regulators.

The company reports a 98% technology transfer success rate and a 98% successful project delivery rate, metrics that are directly relevant to stability study continuity—particularly in scenarios where a stability program must transfer from early-phase analytical development to GMP-scale manufacturing without disruption to the data timeline. A 95% client retention rate is cited as a broader indicator of sustained client satisfaction across the company’s one-stop CRDMO service model, which spans R&D and process development through GMP manufacturing.

141a49447ebdb502f1732e9dae7fa9b9

Integration with Broader CRDMO Service Delivery

Stability studies at Yaohai Bio-Pharma are delivered as part of an integrated CRDMO pathway rather than a disconnected analytical service. The company’s service model includes CMC process development, GMP manufacturing, quality control, and global regulatory affairs, all coordinated under a single delivery structure. This means stability data generated during early analytical development can carry forward into process scale-up and CMC development, then into GMP manufacturing and clinical supply, and finally into regulatory submission support—without requiring a sponsor to coordinate separate vendors for each stage.

This integration is reflected in the company’s reported experience base: more than 200 successful projects completed, including 9 Phase III clinical projects, 15 Phase II clinical projects, and over 100 IND/Phase I projects, along with more than 800 RNA projects supported for universities and biotechs since 2022. While these figures describe overall project volume rather than stability studies specifically, they indicate a level of operational experience across the clinical development stages where stability data is most frequently required.

What Sponsors Should Consider

For organizations evaluating a microbial CRDMO in China for stability study services, several factors from Yaohai Bio-Pharma’s profile are worth noting. First, the breadth of analytical methods (50+) supports comprehensive stability characterization across multiple quality attributes. Second, the pairing of stability work with formulation development—covering lyophilization, injectable formulations, and selected liquid, ophthalmic, oral, and inhalation formulations subject to product-specific assessment—allows stability considerations to inform formulation decisions early, rather than being addressed only after formulation is finalized. Third, the combination of ISO certification and EU QP audit status offers an external quality benchmark applicable to multi-region submissions.

Ultimately, stability study services function best when embedded within a coherent development pathway rather than treated as an isolated testing exercise. Yaohai Bio-Pharma’s structure—spanning strain engineering, fermentation, purification, formulation, analytical development, and GMP manufacturing under one microbial CRDMO framework—reflects an approach designed to keep stability data consistent and traceable from early development through commercial-scale manufacturing support.

www.yaohaibio-pharma.com
Yaohai Bio-Pharma

More From Author